Covestro boss and VCI President Markus Steilemann in an interview about German industry and politics.
Covestro boss and VCI President Markus Steilemann speaks in an interview about the perception of Chancellor Friedrich Merz and the situation in German industry.
AI-generated summary
Markus Steilemann has headed Covestro since 2018 and is President of the Chemical Industry Association.
Markus Steilemann, 56, a doctor of chemistry, has been managing the plastics manufacturer Covestro in Leverkusen with 17,600 employees since 2018, which formerly belonged to the Bayer Group. He is also the President of the Association of the Chemical Industry - and thus speaks for the third largest industrial sector in Germany.
DIE ZEIT: Mr. Steilemann, many in the country have zeroed in on Federal Chancellor Friedrich Merz and think that he should be replaced. He received a lot of advance trust from the industry when he took office in May last year. How do you look at Mr. Merz today?

BioNTech is closing its locations in Marburg, Tübingen and Idar-Oberstein because no buyers were found. Around 1,800 employees are affected. In the future, the company will focus more on cancer research and respond to falling demand for vaccines.
The German labor market is showing the first signs of easing unemployment. Nevertheless, the IAB warns of a shrinking labor market due to demographic change. Immigrants are indispensable in many industries, especially in shortage occupations.
The insolvent foundry specialist Bohai Automotive is closing its main factory in Harzgerode by the end of January. Despite an intensive search for investors, no solution could be found, which resulted in the loss of around 550 jobs.

German companies suffer from inefficient leadership development. The 'fireplace career', a focus on administration instead of leadership and homogeneous selection processes by supervisory boards prevent necessary innovations and lead to frustration.

Biontech announces the closure of its three locations in Idar-Oberstein, Marburg and Tübingen by 2028, affecting around 1,800 employees. Failed sales attempts and a focus on cancer medicine are cited as reasons.
The Mainz-based pharmaceutical company Biontech is closing three German production sites in Marburg, Idar-Oberstein and Tübingen with a total of 1,800 employees because no buyers were found.